Recently, Stephen et al.used the CRISPR-Cas9 technology to screen PARP1 point mutation fragments that lead to PARPi resistance, and they found PARP1 p. R591C mutation (c.1771C>T) in an olaparib-resistant ovarian cancer patient. This evidence concerns the gene PARP1 and ovarian carcinoma.